drugset / Trial / NCT01272414

Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction

NCT01272414 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

Currently there are few therapeutic options for the treatment of lid retraction secondary to thyroid orbitopathy (TO) during the active stages of the disease. BoTox injection is capable of creating a ptosis, that in the setting of TO can return the upper lid to a more physiologic position, thus improving cosmesis, corneal lubrication and potentially quiescent stage lid position. This investigation aims to examine the properties of this relationship.

Timeline

Start
2011-01
Primary completion
2012-01
Completion
2012-02

Outcome

Outcome not reported

Stopped (Business): “lack of funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 2 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 4 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 6 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 8 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 10 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 12 iu —